Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study

Abstract

Sarcopenia is an independent prognostic factor in PDAC patients with a BMI ≥22. Therefore, evaluating skeletal muscle mass may be a simple and useful approach for predicting patient prognosis.

The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients

“…Approximately 73% of patients were sarcopenic at baseline according to previous data, and most of them had normal BMI (median BMI: 24.1 kg/m 2 ). Furthermore, 33% of sarcopenic patients and 35% of patients with early LSMM had a BMI > 25 kg/m 2 .…”

“…PC patients have shorter survival and an increased risk of distant metastases . Furthermore, the prognosis of these patients is conditioned by a higher incidence of malnutrition or cachexia, present in 70–80% of PC patients, responsible for at least 20% of all deaths . In fact, multiple risk factors for loss of skeletal muscle mass (LSMM) due to cancer‐related factors and medical treatment concur to cause more treatment toxicities, asthenia, fatigue, reduced response to cancer therapy, prolonged hospitalization, impaired quality of life, and, therefore, a worse prognosis .…”

“…2,3 Furthermore, the prognosis of these patients is conditioned by a higher incidence of malnutrition or cachexia, present in 70-80% of PC patients, responsible for at least 20% of all deaths. [4][5][6][7] In fact, multiple risk factors for loss of skeletal muscle mass (LSMM) due to cancer-related factors and medical treatment concur to cause more treatment toxicities, asthenia, fatigue, reduced response to cancer therapy, prolonged hospitalization, impaired quality of life, and, therefore, a worse prognosis. 2,6,8,9 However, the identification of patients with muscle loss has become increasingly difficult, because~40-60% of cancer patients are overweight or obese, even in the metastatic setting.…”

“…[4][5][6][7] In fact, multiple risk factors for loss of skeletal muscle mass (LSMM) due to cancer-related factors and medical treatment concur to cause more treatment toxicities, asthenia, fatigue, reduced response to cancer therapy, prolonged hospitalization, impaired quality of life, and, therefore, a worse prognosis. 2,6,8,9 However, the identification of patients with muscle loss has become increasingly difficult, because~40-60% of cancer patients are overweight or obese, even in the metastatic setting. 3 Sarcopenia was defined by Evans as LSMM, which results in decreased strength and aerobic capacity and, thus, functional capacity.…”

Preoperatively Identified Sarcopenia Leads to Increased Postoperative Complications, Hospital and ICU Length of Stay in Autologous Microsurgical Breast Reconstruction

“…3,4 Recently, this condition has been found to be associated with increased adverse perioperative outcomes in the general, thoracic, and transplant surgery literature. [5][6][7][8][9][10][11][12] New methods of identifying sarcopenia through analysis of cross-sectional computed tomography (CT) scans by commercially and publicly available software has been developed. 13 The incidence and significance of sarcopenia has not been evaluated in patients undergoing breast reconstruction with autologous free tissue transfer.…”